E
LFCR icon

Ergoteles’s Lifecore Biomedical LFCR Stock Holding History

Ergoteles’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-51,100
Closed -$494K – 494
2023
Q2 		$494K Buy
+51,100
New +$312K 0.02% 647

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Ergoteles's LFCR Position: Q3 2023 in Review

Ergoteles sold out of Lifecore Biomedical (LFCR) in Q3 2023, closing a stake of 51,100 shares — an estimated $494K sold.

Ergoteles first reported a position in LFCR in Q2 2023 and held it in 1 quarter. The position peaked at $494K in Q2 2023. 69 funds tracked by Wall St. Rank hold LFCR as of Q3 2023.

  • Ergoteles reported no remaining Lifecore Biomedical position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 51,100 Lifecore Biomedical shares in Q3 2023, an estimated $494K.
  • Ergoteles first reported a position in Lifecore Biomedical in Q2 2023 and held it in 1 quarter.
  • Ergoteles's Lifecore Biomedical position peaked at $494K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.